Lexeo Therapeutics, Inc. (LXEO)
4.07
-0.13
(-3.10%)
USD |
NASDAQ |
Sep 21, 16:00
4.07
0.00 (0.00%)
After-Hours: 20:00
Lexeo Therapeutics Total Liabilities (Quarterly) : 19.84M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 19.84M |
| March 31, 2026 | 18.86M |
| December 31, 2025 | 24.46M |
| September 30, 2025 | 23.01M |
| June 30, 2025 | 37.85M |
| March 31, 2025 | 37.58M |
| December 31, 2024 | 33.08M |
| September 30, 2024 | 34.54M |
| Date | Value |
|---|---|
| June 30, 2024 | 27.06M |
| March 31, 2024 | 30.26M |
| December 31, 2023 | 29.64M |
| September 30, 2023 | 32.50M |
| June 30, 2023 | 23.52M |
| March 31, 2023 | 23.97M |
| December 31, 2022 | 29.23M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Oncolytics Biotech, Inc. | 13.84M |
| Sangamo Therapeutics, Inc. | 78.92M |
| Sarepta Therapeutics, Inc. | 1.661B |
| Anixa Biosciences, Inc. | 1.873M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 254.90M |
| Shareholders Equity (Quarterly) | 235.06M |
| Debt to Equity Ratio | 0.029 |
| Current Ratio | 13.89 |
| Net Debt Paydown Yield | 0.14% |